The STARTRK-1, STARTRK-2, and ALKA-372-001 trials accorded the FDA approval to entrectinib via accelerated mode for metastatic ROS1 mutant NSCLC [127, 128]. Here, ROS1 is linked to non-small cell lung carcinoma.